Skip to main content

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)

Tipranks - Tipranks - Thu Nov 27, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Terns Pharmaceuticals (TERN – Research Report) and Ironwood Pharma (IRWD – Research Report).

TipRanks Black Friday Sale

Terns Pharmaceuticals (TERN)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Terns Pharmaceuticals today and set a price target of $33.00. The company’s shares closed last Wednesday at $28.51.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 15.4% and a 51.2% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Terns Pharmaceuticals is a Strong Buy with an average price target of $27.80, implying a -5.8% downside from current levels. In a report issued on November 13, TD Cowen also maintained a Buy rating on the stock.

See the top stocks recommended by analysts >>

Ironwood Pharma (IRWD)

Craig-Hallum analyst Chase Knickerbocker maintained a Hold rating on Ironwood Pharma today. The company’s shares closed last Wednesday at $3.42.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 30.6% and a 55.9% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Avadel Pharmaceuticals, and Diamedica Therapeutics. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Ironwood Pharma with a $3.00 average price target, a -9.9% downside from current levels. In a report issued on November 11, Wells Fargo also maintained a Hold rating on the stock with a $3.00 price target.

Read More on TERN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).